



Improving safe preparation of injectable medicines: the effects of introducing a sporicidal agent

Oweikumo Eradiri and James Margetson
Colchester General Hospital, Essex, U.K.


Abstract Number: PP-005 ATC Code: L01 - Cytostatics

Introduction

- As a consequence of recent fatalities with the use of aseptically-prepared injectable medicines, the MHRA recommended the introduction of a sporicidal agent in the first stage of a two-step decontamination process¹.
- Our licensed Aseptics unit produces chemotherapy, named-patient radiopharmacy and other injectable (CIVAS) doses, using non-gassing isolator (Grade A) technology in a Grade C room environment.
- Traditional GMP environmental monitoring methods are employed, and historical monthly trending revealed a microbial recovery rate of 1.6% across Grade A.

Methods

Disinfectant Specification



Defining Spray and Wipe Process

Old Process

- 1st Stage - Spray (alcohol)
- 2nd Stage - Spray then Wipe


New Process

- 1st Stage - Wipe then Spray (sporicide)
- 2nd Stage - Spray (alcohol) then Wipe

Impact Monitoring


Microbiological Trend Report

Aseptics Area : Grade A Isolators
July 2016




Results


Grade A Impact



Grade A Organism Recovery Ratio



Preparation Room Impact



Outcomes

- 3% reduction in ratio of spore-formers to vegetative organisms
- 20% reduction in overall contamination
- 50% improvement in microbial air quality in Grade C isolator rooms
- 70% improvement in microbial air quality in Grade D preparation rooms
- 100% elimination of moulds in Grade A

Conclusion

A simple change of the sanitisation practice to a more robust wipe-spray-spray-wipe process, using a chlorine-based sporicidal agent for the first 'spray' step, significantly improves the background environmental conditions, reducing the risk of contamination, and thereby ensuring that injectable medicines are prepared safely for the benefit of patients.

Reference

1. Medicines and Healthcare products Regulatory Agency (MHRA) (2015) Guidance for Specials Manufacturers (accessed 07.02.17) https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/400232/Guidance_for_specials_manufacturers.pdf

Contact

oweikumo.eradiri@colchesterhospital.nhs.uk
+44 1206 74 2744